Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatment
Open Access
- 28 December 2007
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (1), 88-97
- https://doi.org/10.1002/art.23167
Abstract
Objective Continuous treatment with the anti–tumor necrosis factor α (anti‐TNFα) antibody infliximab is efficacious in ankylosing spondylitis (AS), whereas treatment discontinuation results in disease relapse, with variable delay. This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested. Methods Patients with active AS were randomly assigned at week 0 to receive infliximab every 6 weeks (continuous treatment) or upon symptom recurrence (on‐demand treatment), following infusions at weeks 4, 6, and 10. Patients in the on‐demand group were randomly assigned to receive either MTX in combination with infliximab or infliximab alone. Patients were monitored for 1 year. The primary end point was the proportion of patients who met the ASsessment in AS International Working Group criteria for 20% improvement (ASAS20) at week 58. Results Of 247 patients, 124 were assigned to receive infliximab every 6 weeks and 123 to receive on‐demand treatment. Among the latter, 62 received MTX, and 61 received infliximab alone. A greater proportion of patients receiving infliximab every 6 weeks fulfilled ASAS20 response criteria at week 58 than did patients receiving on‐demand treatment (75% versus 46%; P < 0.0001). Patients in the continuous treatment group received more infliximab infusions after week 10 than did those in the on‐demand group (mean ± SD 5.8 ± 2.2 versus 3.5 ± 2; P < 0.0001). Addition of MTX did not significantly affect the proportion of patients with an ASAS20 response at week 58, nor the number of infliximab infusions administered. Conclusion These findings indicate that continuous treatment of AS with infliximab is more efficacious than on‐demand treatment, and that the addition of MTX to infliximab provides no significant benefit.Keywords
This publication has 35 references indexed in Scilit:
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's diseaseGut, 2007
- No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trialAnnals Of The Rheumatic Diseases, 2007
- Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formationAnnals Of The Rheumatic Diseases, 2006
- Infliximab Therapy for Patients With Active and Refractory Spondyloarthropathies at the Dose of 3 mg/kgJCR: Journal of Clinical Rheumatology, 2004
- Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working ageAnnals Of The Rheumatic Diseases, 2003
- Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: A cross‐sectional studyArthritis & Rheumatism, 2003
- Therapy for ankylosing spondylitis: new treatment modalitiesBest Practice & Research Clinical Rheumatology, 2002
- Ankylosing spondylitis and current disease-controlling agents: do they work?Best Practice & Research Clinical Rheumatology, 2002
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984